Somatic Mutation of Epidermal Growth Factor Receptor in a Small Subset of Cutaneous Squamous Cell Carcinoma
Open Access
- 1 March 2010
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 130 (3) , 901-903
- https://doi.org/10.1038/jid.2009.312
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancerBritish Journal of Cancer, 2007
- Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromesOncogene, 2007
- A module of negative feedback regulators defines growth factor signalingNature Genetics, 2007
- Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl‐Akt, and phosphoryl‐MAPK, and on the prognosis of patients with non‐small cell lung cancerJournal of Surgical Oncology, 2006
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humansHuman Molecular Genetics, 2005
- Skin Cancers after Organ TransplantationNew England Journal of Medicine, 2003
- No evidence of somatic FGFR3 mutation in various types of carcinomaOncogene, 2001
- Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor developmentOncogene, 2000
- Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomasOncogene, 2000